LYEL
Lyell Immunopharma, Inc.
NASDAQ · USHealthcareBiotechnology
$12.92-3.00%
Price as of Jul 20, 2026
LYEL financials
Lyell Immunopharma, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $36.0K | $61.0K | $130.0K | $84.7M |
| Cost of revenue | $11.5M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$11.5M | $61.0K | $130.0K | $84.7M |
| Operating expenses | $192.3M | $358.8M | $247.1M | $271.7M |
| Operating income | -$203.8M | -$358.8M | -$247.0M | -$187.1M |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M |
| EBITDA | -$262.9M | -$200.6M | -$214.4M | -$165.1M |
| Basic EPS | $-16.06 | $-1.31 | $-0.93 | $-0.74 |
| Diluted EPS | $-16.06 | $-1.31 | $-0.93 | $-0.74 |
| Balance sheet | ||||
| Cash & equivalents | $60.2M | $105.6M | $145.6M | $123.6M |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M |
| Stockholders’ equity | $248.2M | $382.8M | $655.0M | $833.3M |
| Total debt | $51.0M | $59.0M | $63.2M | $67.7M |
| Net debt | -$9.2M | -$46.6M | -$82.5M | -$55.9M |
| Cash flow | ||||
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M |
| Capital expenditure | -$780.0K | -$464.0K | -$2.7M | -$24.3M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |